Targeting NASHAdvances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
Byrne CD, Targher G. J Hepatol. 2015;62(suppl 1):S47-S64.
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
Friedman SL, et al. Hepatology. 2017 Aug 17. [Epub ahead of print].
Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Hannah WN Jr, Harrison SA. Hepatology. 2016;64(6):2234-2243.
Elevated serum ferritin is an independent predictor of histologic severity and advanced fibrosis among patients with nonalcoholic fatty liver disease.
Kowdley KV, et al. Hepatology. 2012;55(1):77-85.
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial.
Loomba R, et al. Hepatology. 2017 Sep 11. [Epub ahead of print].
Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
Mohamad B, et al. Hepatol Int. 2016;10(4):632-639.
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
Neuschwander-Tetri BA, et al. Lancet. 2015;385(9972):956-965.
Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening.
Ratziu V, et al. Gastroenterology. 2016;150(5):1147-1159.
Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.
Ratziu V, et a. Hepatology. 2010;51(2):445-453.
Rinella ME, Sanyal AJ. Nat Rev Gastroenterol Hepatol. 2016;13(4):196-205.
Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.
Targher G, et al. Diabetes. 2005;54(12):3541-3546.
VanWagner LB, Rinella ME. Curr Hepatol Rep 2016;15(2):75- 85.
Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.
Wong RJ, et al. Gastroenterology. 2015;148(3):547-555.
Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes.
Younossi ZM, et al. Hepatology. 2016;64(1):73-84.
Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality.
Younossi ZM, et al. Hepatology. 2011;53(6):1874-1882.
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
Got it? Treat it!
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
The Emerging Role of the Diabetologist
Key Issues Impacting OB/GYN Practice
An Interactive Experience Highlighting Recent Clinical Advances
Hot Topics in HBV, HCV, and NASH
Emerging Concepts in Patient Management
Building Your Understanding to Combat a Growing Problem
Why It Matters in OB/GYN Practice Today
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
The PCP’s Role in HCV Elimination
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
An Interactive Learning Experience
A Focus on Clinical Evidence and Guideline Recommendations
A Multidisciplinary Online Mini-Curriculum
Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
A Multidisciplinary Look at Early Diagnosis and Management
Best Practices for Diagnosis and Management